Renal Cell Carcinoma
BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC
A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Investigator: Scott Tykodi, MD; Conditions: Kidney Cancer; Status: Recruiting; Study ID: NCT01668784
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Investigator: Shailender Bhatia, M.D.; Conditions: Renal Cell Carcinoma; Status: Recruiting; Study ID: NCT01034631
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
Investigator: Ajay K. Gopal, MD; Conditions: Non-Hodgkin's Lymphoma (NHL); Status: Recruiting; Study ID: NCT01307267
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors
Investigator: Laura Chow, MD; Conditions: Neoplasms by Site; Status: Recruiting; Study ID: NCT01629758
A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Investigator: John A. Thompson, MD; Conditions: Renal Cell Carcinoma; Status: Recruiting; Study ID: NCT01672775
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Investigator: John A. Thompson, MD; Conditions: Renal Cell Carcinoma; Status: Recruiting; Study ID: NCT01677390
Join Us On